Cancer Stem Cells Market Size & Share Analysis - Growth Trends And Forecasts (2024 - 2029)

The Cancer Stem Cells Market Report is Segmented by Cancer Type (Breast, Blood, Lung, Brain, Colorectal, Pancreatic, Bladder, Liver, and Other Cancer Types), Application (Targeted Cancerous Stem Cells (CSCs) and Stem Cell-Based Cancer Therapy), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (USD) for the Above Segments.

Cancer Stem Cells Market Size

Cancer Stem Cells Market Summary
Study Period 2024 - 2029
Market Size (2024) USD 2.35 Billion
Market Size (2029) USD 4.09 Billion
CAGR (2024 - 2029) 11.76 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration High

Major Players

Cancer Stem Cells Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Cancer Stem Cells Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Cancer Stem Cells Market Analysis

The Cancer Stem Cells Market size is estimated at USD 2.35 billion in 2024, and is expected to reach USD 4.09 billion by 2029, growing at a CAGR of 11.76% during the forecast period (2024-2029).

The increasing burden of cancer and fostering research and development (R&D) efforts by biopharmaceutical companies are projected to drive the cancer stem cell market. Moreover, increased focus on developing targeted therapies for cancer and fostering demand for personalized medicine has further accelerated the market's growth. For instance, in February 2022, the University of California, Irvine, established the Institute for Precision Health to deliver the most effective wellness strategy for individuals.

The institute focuses on precision health informatics and cancer stem cell therapeutics. Similarly, in June 2023, the National Cancer Institute (NCI) introduced the precision medicine initiative ComboMATCH for cancer patients. This approach involves knowledge of the patient’s tumor biology to decide the right combination of treatments for a patient. This information is critical in developing a regime that specifically targets cancer stem cells, thereby improving the treatment's outcome.

In recent years, stem cells have been used effectively in blood replenishment and immuno-reconstitution after cancer treatment. Also, these cells have gained remarkable traction across healthcare professionals for their role as a modality for delivering anti-tumor agents and their implication in tissue regeneration. A significant number of entities have reported positive outcomes of implementing this mode of tumor treatment. For instance, according to DVC Stem (Da Vinci Wellness Center) data published in October 2023, stem cells have shown promising outcomes in cancer, and approximately 87.5% of people reported improvement in their condition.

Similarly, in May 2023, a senior hematologist from Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, demonstrated the role of stem cells in the management of blood cancers and also emphasized their roles in successful treatments. Thus, the evolving landscape of stem cell therapies in cancer and the higher adoption of stem cell implants by healthcare professionals are likely to cater to the market's growth during the study period.

Moreover, the exponential rise in cancer cases facilitated the demand for advanced cancer therapeutics, including stem cell therapies. For instance, according to estimates from the National Cancer Institute of Brazil, around 704 thousand new cancer cases are expected to be diagnosed between 2023 and 2025, except non-melanoma skin cancer. The most diagnosed cancers in the country were prostate cancer, lung cancer, and breast cancer.

Thus, it has become very crucial to develop an efficient treatment to regulate cancer and improve the standard of living of cancer patients. Various public and private organizations are actively involved in the introduction of innovative solutions for the treatment of cancer. For instance, in October 2022, Bristol Myers Squibb (BMS) and Century Therapeutics formed a research collaboration to manufacture and commercialize four iPSC-derived (induced pluripotent stem cell) T-cell or natural killer cell programs for solid tumors and hematologic malignancies.

Furthermore, the growing research efforts and funding activities for stem cell research are expected to bolster the market's growth during the study period. For instance, in May 2024, the City of Hope received USD 5.4 million from the California Institute for Regenerative Medicine (CIRM) to build a stem cell research laboratory in the United States to expand research capabilities in cancer stem cell research. Such activities are further anticipated to foster the market's growth over the projected period.

Thus, the above-mentioned factors, such as the growing burden of cancer across the world and the growing efforts to develop targeted stem cell therapies for cancer, are anticipated to drive the market's growth.

However, factors such as the high cost of therapy and less penetration in low-and middle-income countries are anticipated to hamper the growth during the forecast period.

Cancer Stem Cells Market Trends

The Breast Cancer Segment is Expected to Hold a Major Share in the Market

The breast cancer segment is projected to hold the largest revenue share of the cancer stem cells market, and it is expected to register an exponential growth rate during the forecast period. The growing burden of breast cancer, ongoing research advancements to understand the role of stem cells in cancer, and increased awareness about early cancer diagnosis are driving the segment's growth.

According to the American Cancer Society, the burden of breast cancer increased significantly in the United States, and the total number of cases ramped from 300,590 in 2023 to 313,510 in 2024. In addition, according to 2023 updated data from the Global Cancer Observatory, around 29,249 new breast cancer cases are expected to be diagnosed in Argentina in 2045. This alarming rise in breast cancer cases has shed light on developing novel approaches to address new and relapsed conditions.

For instance, in January 2023, researchers found new ways to remarkably improve the effectiveness of breast cancer treatment by targeting a common protein variant. In this study, scientists found that the RAC1B protein makes the disease more resistant to treatment and can relapse.

However, targeting more RAC1B proteins can effectively transform the breast cancer treatment landscape. In addition, in June 2023, a study published by the Cancer Discovery journal demonstrated that circulating stem cells can lead to metastatic disease and may produce chemotherapy resistance. Thus, the evolving research landscape to understand the role of circulating stem cells in breast cancer helped researchers to investigate novel treatment approaches, thereby accelerating the segment's growth.

Moreover, the fostering demand for personalized therapies for breast cancer and various organic and inorganic developments undertaken by leading market players to develop advanced therapies have further contributed to the segment expansion.

Thus, owing to the above-mentioned factors, such as the growing burden of breast cancer across the world and increased research efforts to understand the role of stem cells in breast cancer treatment, are projected to accelerate the segment's expansion during the study period.

Cancer Stem Cells Market:  Number of New Breast Cancer Cases (In Million), United States, 2022 - 2024

North America is Expected to Exhibit Significant Growth Opportunities in the Market

North America is expected to hold a lucrative market share in the cancer stem cells market owing to factors such as advanced healthcare infrastructure and several organizations engaged in research and development (R&D) activities related to stem cells. Also, the alarming burden of cancer in the region, coupled with supportive government legislation for cancer research, is further contributing to the regional market.

The alarming rise in the burden of cancer is expected to offer significant growth opportunities for the market. For instance, according to the American Cancer Society, the estimated number of new cancer cases increased from 1.9 million in 2023 to 2.0 million in 2024. The most common type of cancers diagnosed in 2023 were breast, lung, and hematological malignancies. In addition, according to the 2024 updated data from the Canadian Cancer Society, the number of cancer cases in Canada increased from 239,100 in 2023 to 247,100 in 2024. This alarming rise in cancer cases is anticipated to fuel research activities in stem cell research, which is expected to fuel the market's growth.

The rising emphasis on understanding stem cells' roles in the management of cancer has attracted researchers to develop cell-based cancer therapies. For instance, in May 2024, researchers from the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research received a grant of USD 17.4 million from the California Institute for Regenerative Medicine to advance stem cell-based therapies for the management of cancers.

Moreover, a supportive regulatory framework coupled with rising demand for advanced therapeutics further fosters the regional market. For instance, in September 2023, the US FDA approved Motixafortide for use with filgrastim as part of a stem cell transplant formulation. The approval is based on positive clinical trial results. In addition, in June 2023, StemCyte signed an agreement with a leading cell therapy company to supply raw materials used in drug formulation for allogeneic-modified cell therapy. This initiative will help the company to capture novel market avenues, thereby fueling the regional market.

Therefore, factors such as the higher burden of cancer in the region and various strategic initiatives undertaken by leading participants are projected to support the regional market during the forecast period.

Cancer Stem Cells Market- Growth Rate By Region

Cancer Stem Cells Industry Overview

The cancer stem cells market is semi-consolidated in nature due to the presence of several companies operating globally and regionally. Players operating in the cancer stem cells market undertake several organic and inorganic growth strategies to bolster their business avenues. Some of the key players operating in the cancer stem cells market are Thermo Fisher Scientific Inc., Merck KGaA, Bio-Techne (R&D Systems Inc., and Lonza.

Cancer Stem Cells Market Leaders

  1. Thermo Fisher Scientific Inc.

  2. Merck KGaA

  3. Lonza

  4. PromoCell GmbH

  5. Bio-Techne (R&D Systems, Inc.)

*Disclaimer: Major Players sorted in no particular order

Cancer Stem Cells Market Concentration
Need More Details on Market Players and Competitors?
Download PDF

Cancer Stem Cells Market News

  • May 2024: Stanford Medicine treated a patient with the US FDA-approved cell-based stem cell therapy for the management of blood cancer and melanoma.
  • April 2023: Gamida Cell Ltd, a cell therapy leader, announced the US FDA approval of Omisirge, an allogeneic cell therapy for treating pediatric patients and adults with hematologic malignancies. This approval is expected to increase stem cell transplant access and improve patient outcomes.

Cancer Stem Cells Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Burden of Cancer and Supportive Government Legislation For Stem Cell Research

      2. 4.2.2 Rising R&D Efforts and Increasing Awareness Regarding Novel Cancer Regimens

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of the Therapy

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 5.1 By Cancer Type

      1. 5.1.1 Breast

      2. 5.1.2 Blood

      3. 5.1.3 Lung

      4. 5.1.4 Brain

      5. 5.1.5 Colorectal

      6. 5.1.6 Pancreatic

      7. 5.1.7 Bladder

      8. 5.1.8 Liver

      9. 5.1.9 Other Cancer Types

    2. 5.2 By Application

      1. 5.2.1 Autologous SC Transplant

      2. 5.2.2 Allogeneic SC Transplant

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Thermo Fisher Scientific Inc.

      2. 6.1.2 Merck KGaA

      3. 6.1.3 Bio-Techne (R&D Systems Inc.)

      4. 6.1.4 Lonza

      5. 6.1.5 Miltenyi Biotec

      6. 6.1.6 PromoCell GmbH

      7. 6.1.7 MacroGenics Inc.

      8. 6.1.8 FUJIFILM Irvine Scientific

      9. 6.1.9 AcceGen

      10. 6.1.10 Celprogen Inc.

      11. 6.1.11 ATCC

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Cancer Stem Cells Industry Segmentation

As per the scope of the report, cancer stem cells are a subpopulation of cancer cells characterized by their ability to self-renew and differentiate into various cell types, driving tumor growth and recurrence. Their unique properties contribute to treatment resistance and pose significant challenges in developing effective cancer therapies.

The cancer stem cells market is segmented by cancer type, application, and geography. Based on cancer type, the market is segmented as breast, blood, lung, brain, colorectal, pancreatic, bladder, liver, and other cancer types. Based on application, the market is segmented into targeted cancerous stem cells (CSCs) and stem cell-based cancer therapy. Based on geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America.

The report also covers the market sizes and forecasts for the cancer stem cells market in major countries across different regions. The market size is provided in terms of value (USD) for each segment.

By Cancer Type
Breast
Blood
Lung
Brain
Colorectal
Pancreatic
Bladder
Liver
Other Cancer Types
By Application
Autologous SC Transplant
Allogeneic SC Transplant
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Cancer Stem Cells Market Research FAQs

The Cancer Stem Cells Market size is expected to reach USD 2.35 billion in 2024 and grow at a CAGR of 11.76% to reach USD 4.09 billion by 2029.

In 2024, the Cancer Stem Cells Market size is expected to reach USD 2.35 billion.

Thermo Fisher Scientific Inc., Merck KGaA, Lonza, PromoCell GmbH and Bio-Techne (R&D Systems, Inc.) are the major companies operating in the Cancer Stem Cells Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Cancer Stem Cells Market.

In 2023, the Cancer Stem Cells Market size was estimated at USD 2.07 billion. The report covers the Cancer Stem Cells Market historical market size for years: . The report also forecasts the Cancer Stem Cells Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Cancer Stem Cells Industry Report

Statistics for the 2024 Cancer Stem Cells market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Cancer Stem Cells analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Cancer Stem Cells Market Size & Share Analysis - Growth Trends And Forecasts (2024 - 2029)